Sign up to save your podcasts
Or
Share Immune Matters Episode 1, Blachy and Jessie, Wiskott Aldrich
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Immune Matters Episode 1, Blachy and Jessie, Wiskott Aldrich
In this episode of Immune Matters: a PIDTC Podcast, Dr. Jack McDonnell and Dr. Elie Haddad, along with guests Dr. Blachy Davila and Dr. Jessie Alexander, delve into Wiskott-Aldrich syndrome, a rare X-linked immunodeficiency affecting boys. They discuss the clinical manifestations, management strategies, and the importance of bone marrow transplantation as a definitive treatment. The conversation highlights a recent study analyzing transplant outcomes and conditioning regimens, emphasizing the need for timely intervention and collaboration in research to improve patient care.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.
View all episodes
By Jack McDonnellIn this episode of Immune Matters: a PIDTC Podcast, Dr. Jack McDonnell and Dr. Elie Haddad, along with guests Dr. Blachy Davila and Dr. Jessie Alexander, delve into Wiskott-Aldrich syndrome, a rare X-linked immunodeficiency affecting boys. They discuss the clinical manifestations, management strategies, and the importance of bone marrow transplantation as a definitive treatment. The conversation highlights a recent study analyzing transplant outcomes and conditioning regimens, emphasizing the need for timely intervention and collaboration in research to improve patient care.
The Primary Immune Deficiency Treatment Consortium (PIDTC) is a part of the Rare Diseases Clinical Research Network of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH).
This work was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (DAIT, NIAID) and the ORDR under cooperative agreements U54-AI082973 and U54-NS064808 and grants R13-AI094943 and 1R24AI184316-01.
The content and opinions expressed are solely the responsibility of the authors and do not represent the official policy or position of the NIAID, ORDR, NCATS, NIH, HRSA, or any other agency of the US Government.